

Streamline Health® Reports Second Quarter 2016 Revenues of \$7.4 Million; Adjusted EBITDA of \$1.6 Million; Net Loss of \$(0.7) Million

Total First Half Fiscal 2016 Revenue \$14.0 Million; Adjusted EBITDA \$2.2 Million; Net Loss of \$(2.2) Million

ATLANTA, Sept. 7, 2016 /PRNewswire/ -- <u>Streamline Health Solutions, Inc.</u> (NASDAQ: STRM), provider of the Looking Glass® platform of integrated solutions, technology-enabled services and analytics supporting revenue cycle optimization for healthcare enterprises in the new value-based world today announced financial results for the second quarter and first half of fiscal 2016, which ended July 31, 2016.



Revenues for the three-month period ended July 31, 2016 were \$7.4 million, up approximately 10% over \$6.7 million in Q1 2016, but down approximately 14% as compared to \$8.6 million in the same quarter a year ago, which included \$1.6 million of perpetual license revenue as compared to \$1.0 million of perpetual license revenue in the current quarter. Recurring revenue comprised 76.7% of total revenue in the quarter. Revenues for the first six months of fiscal year 2016 were \$14.0 million, down approximately 5.1% versus the first half of fiscal 2015.

Adjusted EBITDA for the second quarter 2016 was \$1.6 million, up appreciably from \$0.6 million in Q1, but down approximately 21% from \$1.9 million in second quarter of 2015. Net loss for the second quarter was \$(0.7) million, down from \$(0.6) million a year prior. Adjusted EBITDA for the first six months of 2016 was \$2.2 million, a significant increase over \$0.6 million in the first half of fiscal 2015. Net loss for the first half of 2016 was \$(2.2) million, an improvement from \$(2.4) million for first half of 2015.

"Our second quarter financial performance was a solid improvement over the first quarter of this year as expected, with revenue up nicely and Adjusted EBITDA up significantly" stated David Sides, President and Chief Executive Officer, Streamline Health. "Bookings improved materially over first quarter to \$1.7 million. As previously communicated, we believe our bookings will accelerate in the second half of this fiscal year as our investment in sales and marketing takes hold."

Highlights for the second quarter ended July 31, 2016 included:

- Revenue for the second quarter 2016 was \$7.4 million;
- Adjusted EBITDA for the second quarter 2016 was \$1.6 million;
- Net loss for the second guarter 2016 was \$(0.7) million;
- New sales bookings for the quarter were \$1.7 million; and
- Backlog at the end of the guarter was \$53.6 million.

Conference Call Information

The Company will conduct a conference call to review the results on Wednesday, September 7, 2016 at 5:00 PM ET. Interested parties can access the call by joining the live webcast: <u>click here</u> to register. You can also join by phone by dialing 877-857-6161 and then entering passcode 7923166.

A replay of the conference call will be available from Wednesday, September 7, 2016 at 8:00 PM ET to Monday, September 12, 2016 at 8:00 PM ET by dialing 888-203-1112 and entering passcode 7923166.

*Non-GAAP Financial Measures

Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP").

Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that this measure provides useful supplemental information regarding the performance of Streamline Health's business operations.

Streamline Health defines "adjusted EBITDA" as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, transaction expenses and other expenses that do not relate to Streamline Health's core operations. A table illustrating this measure is included in this press release.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge - actionable insights that support revenue cycle optimization for healthcare enterprises. Our Looking Glass® platform delivers integrated solutions and analytics that enable providers to drive reimbursement in a value-based world. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's estimates of future revenue, backlog, results of investments in sales and marketing and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Company Contact:

Randy Salisbury SVP, Chief Marketing Officer (404) 229-4242 randy.salisbury@streamlinehealth.net

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Three Months Fuded

Civ Mantha Fudad

	_	I nree Months Ended July 31,					Six Months Ended July 31,			
	enues: 2016 2015 sterns sales \$ 1,364,771 \$ 1,941,601 \$ efessional services 548,080 659,372 <t< th=""><th>2016</th><th></th><th>2015</th></t<>	2016		2015						
Revenues:										
Systems sales	\$	1,364,771	\$	1,941,601	\$	1,876,038	\$	2,240,217		
Professional services		548,080		659,372		1,238,695		1,010,331		
Maintenance and support		3,732,488		3,627,118		7,488,041		7,281,183		
Software as a service	_	1,728,724	_	2,391,008	_	3,438,510	_	4,256,810		
Total revenues	-	7,374,063	-	8,619,099	-	14,041,284	-	14,788,541		
Operating expenses:										
Cost of systems sales		671,631		694,794		1,417,115		1,421,585		

Cost of professional services	529,024	647,569	1,167,788	1,419,065
Cost of maintenance and support	835,353	714,273	1,693,171	1,531,178
Cost of software as a service	455,370	702,769	939,613	1,441,600
Selling, general and administrative	3,341,949	3,779,114	6,940,790	8,285,288
Research and development	2,108,567	2,233,356	3,830,754	4,457,549
Total operating expenses	7,941,894	8,771,875	15,989,231	18,556,265
Operating loss	(567,831)	(152,776)	(1,947,947)	(3,767,724)
Other expense (income):				
Interest expense	(120,014)	(248,175)	(282,026)	(492,116)
Miscellaneous income (expenses)	(44,756)	(159,814)	21,466	1,829,160
Loss before income taxes	(732,601)	(560,765)	(2,208,507)	(2,430,680)
Income tax benefit (expense)	(1,701)	(3,414)	(3,402)	468
Net loss	\$ (734,302)	\$ (564,179)	\$ (2,211,909)	\$ (2,430,212)
Less: deemed dividends on Series A Preferred Shares	(418,506)	(325,018)	(803,225)	(620,675)
Net loss attributable to common shareholders	\$ (1,152,808)	\$ (889,197)	\$ (3,015,134)	\$ (3,050,887)
Basic net loss per common share	\$ (0.06)	\$ (0.05)	\$ (0.16)	\$ (0.16)
Number of shares used in basic per common share computation	19,791,805	18,628,288	19,393,547	18,614,622
Diluted net loss per common share	\$ (0.06)	\$ (0.05)	\$ (0.16)	\$ (0.16)
Number of shares used in diluted per common share computation	19,791,805	18,628,288	19,393,547	18,614,622

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Assets

		July 31, 2016		January 31, 2016
Current assets:				
Cash and cash equivalents	\$	6,513,326	\$	9,882,136
Accounts receivable, net of allowance for doubtful				
accounts of \$204,654 and \$155,407, respectively		3,800,134		4,199,315
Contract receivables		81,343		119,697
Prepaid hardware and third-party software for				
future delivery		5,992		5,858
Prepaid client maintenance contracts		840,908		956,913
Other prepaid assets		1,208,222		941,532
Other current assets	-	3,835	_	97,986
Total current assets		12,453,760	_	16,203,437
Non-current assets:				
Property and equipment:				
Computer equipment		2,689,226		2,647,135
Computer software		807,813		801,895
Office furniture, fixtures and equipment		683,443		683,443
Leasehold improvements		729,348		729,348
Leaderloid improvements		4,909,830	-	4,861,821
Accumulated depreciation and amortization		(3,026,510)		(2,407,746)
Property and equipment, net		1,883,320	-	2,454,075
Troperty and equipment, het		1,000,020	-	2,404,073
Contract receivables, less current portion		_		8,711
Capitalized software development costs, net of				
accumulated amortization of \$16,345,910 and				
\$14,919,948, respectively		5,634,236		6,123,638
Intangible assets, net of accumulated amortization of				
\$5,322,567 and \$4,671,675, respectively		7,504,433		8,155,325
Deferred financing costs, net of accumulated				
amortization of zero and \$84,531, respectively		_		270,147
Goodwill		16,184,667		16,184,667
Other		824,032	-	746,018

32,030,688 \$ 44,484,448 \$ 50,146,018

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Liabilities and Stockholders' Equity

July 31, Janua 2016 20	ary 31, 16
Current liabilities:	
Accounts payable \$ 733,179 \$ 1,13	36,779
Accrued compensation 542,120 93	35,324
Accrued other expenses 238,401 32	28,551
Current portion of long-term debt 786,108 67	73,807
Deferred revenues 9,982,283 10,44	17,280
Current portion of capital lease obligation 223,749 59	92,642
Total current liabilities 12,505,840 14,11	14,383
Non-current liabilities:	
Term loans 5,438,932 7,86	61,084
Warrants liability 143,257 20	05,113
Royalty liability 2,355,998 2,29	91,888
Lease incentive liability 364,500 36	59,406
Capital lease obligation 23,188 9	93,257
Deferred revenues, less current portion 918,295 1,21	12,709
Total non-current liabilities 9,244,170 12,03	33,457
Total liabilities <u>21,750,010</u> <u>26,14</u>	17,840
Series A 0% Convertible Redeemable Preferred stock, \$.01 par value per share, \$8,849,985 redemption value, 4,000,000 shares authorized, 2,949,995 issued and outstanding, net of unamortized preferred stock discount of \$72,710 and \$875,935, respectively 8,777,275 7,97	74,050
Stockholders' equity:	
Common stock, \$.01 par value per share, 45,000,000 shares authorized, 19,639,774 and 18,783,540 shares issued and	
outstanding, respectively 196,398 18	37,836
	00,577
Accumulated deficit (66,076,194) (63,86	4,285)
<u></u>	24,128
	16,018

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Six Months	En	ded July 31,
	2016		2015
Operating activities:			
Net loss	\$ (2,211,909)	\$	(2,430,212)
Adjustments to reconcile net loss to net cash			
provided by (used in) operating activities:			
Depreciation	630,706		625,239
Amortization of capitalized software development costs	1,425,962		1,557,758
Amortization of intangible assets	650,892		674,460
Amortization of other deferred costs	115,113		83,868

Valuation adjustment for warrants liability		(61,856)		(1,268,084)
Share-based compensation expense		909,411		1,283,459
Other valuation adjustments		83,937		94,351
Loss on disposal of property and equipment		567		34,228
Gain on early extinguishment of lease liability		_		(33,059)
Provision for accounts receivable		88,472		89,002
Deferred tax benefit		_		(9,574)
Changes in assets and liabilities, net of assets acquired:				
Accounts and contract receivables		357,774		(2,122,715)
Other assets		(214,327)		319,862
Accounts payable		(403,600)		427,914
Accrued expenses		(472,420)		(276,301)
Deferred revenues		(759,411)		1,759,832
Net cash provided by operating activities		139,311		810,028
Investing activities:				
Purchases of property and equipment		(60,518)		(117,182)
Capitalization of software development costs		(936,560)		
Net cash used in investing activities		(997,078)		(117,182)
Financing activities:				
Principal repayments on term loan		(2,075,172)		(990,506)
Principal payments on capital lease obligation		(438,962)		(403,701)
Recovery of deferred financing costs		(100,002)		2,111
Proceeds from exercise of stock options and stock purchase plan		14,793		207,779
Payments related to settlement of employee shared-based awards		(11,702)		
Net cash used in financing activities		(2,511,043)		(1,184,317)
Decrease in cash and cash equivalents		(3,368,810)		(491,471)
Cash and cash equivalents at beginning of period		9,882,136		6,522,600
Cash and cash equivalents at end of period	\$	6,513,326	\$	6,031,129
Cash and cash equivalents at one of period	Ψ		Ψ	, ,

STREAMLINE HEALTH SOLUTIONS, INC. Backlog (Unaudited) Table A

	July 31, 2016	January 31, 2016	July 31, 2015	
Streamline Health Software Licenses	\$ 15,133,000	\$ 21,586,000	\$ 20,996,000	
Third Party Hardware and Software	200,000	200,000	220,000	
Professional Services	5,563,000	5,803,000	5,934,000	
Maintenance and Support	19,569,000	23,292,000	22,921,000	
Software as a Service	13,177,000	16,264,000	19,600,000	
Total	\$ 53,642,000	\$ 67,146,000	\$ 69,671,000	

STREAMLINE HEALTH SOLUTIONS, INC. New Bookings (Unaudited) Table B

Three Months Ended July 31, 2016

		% of Total
	Value	Bookings
Streamline Health Software licenses	\$ 413,000	24%
Software as a service		0%
Maintenance and support	649,000	38%

Reconciliation of Non-GAAP Financial Measures (Unaudited) Table C

This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Non-GAAP financial measures are used by Streamline Health's management in its operating and financial decision-making because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent manner the Company's current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company's management compensates for these limitations by considering the company's financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release. Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associa

Reconciliation of net earnings (loss) to non-GAAP adjusted EBITDA (in thousands)

Net loss July 31,2016 X (2,32) \$ (2,34)	Adjusted EBITDA Reconciliation	TDA Reconciliation Three Months Ended,				Six Months Ended,					
Interest expense			July 31, 2016		July 31, 2015		July 31, 2016		July 31, 2015		
Income tax expense	Net loss	\$	(734)	\$	(564)	\$	(2,212)	\$	(2,430)		
Depreciation of capitalized software development costs	Interest expense		120		248		282		492		
Amortization of capitalized software development costs 710 775 1,426 1,558 Amortization of intangible assets 325 337 651 674 Amortization of other costs 36 77 80 48 EBITDA 769 1,1117 861 967 Share-based compensation expense 432 631 909 1,283 Loss on disposal of fixed assets 768 769 1,1117 861 967 1,283 Associate severances and other costs relating to transactions or corporate restructuring 110 67 110 206 Non-cash valuation adjustments to assets and liabilities 78 236 70 255 20 (1,173) Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 (1,173) Adjusted EBITDA per diluted share Loss per share 1 diluted Share 2 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	Income tax expense		2		3		3		_		
Amortization of intangible assets 325 337 651 674	Depreciation		310		311		631		625		
Amortization of intangible assets 325 337 651 674 Amortization of other costs 36 7 80 48 EBITDA 769 1,117 861 967 Share-based compensation expense 432 631 909 1,283 Loss on disposal of fixed assets — 1 1 34 Associate severances and other costs relating to transactions or corporate restructuring 110 67 110 206 Non-cash valuation adjustments to assets and liabilities 14 49 22 (1,173) Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 Other non-recurring income — — — — — (750) Adjusted EBITDA Margin ⁽¹⁾ 21% 22% 15% 587 Adjusted EBITDA per diluted share Loss per share - diluted Adjusted EBITDA per adjusted diluted share (2) \$ 0.06 \$ 0.06 \$ 0.05 \$ 0.16 \$ 0.03 Diluted weighted average shares 19,791,805 18,628,288 19,393,547 18,614,622 Biluted weighted average shares 19,791,805 18,628,288 3,313,870 2,623,593	Amortization of capitalized software										
Amortization of other costs 36 7 80 48 EBITDA 769 1,1117 861 967 Share-based compensation expense 432 631 909 1,283 Loss on disposal of fixed assets - 1 1 34 Associate severances and other costs relating to transactions or corporate restructuring 110 67 110 206 Non-cash valuation adjustments to assets and liabilities 14 49 22 (1,1,73) Transaction related professional fees, advisory fees and other internal direct costs Other non-recurring income - 2 236 7 255 20 Other non-recurring income (750) Adjusted EBITDA Margin ⁽¹⁾ 2 156 587 Adjusted EBITDA per diluted share Loss per share - diluted shares - 19,791,805 18,628,288 19,393,547 18,614,622 Diluted weighted average shares 19,791,805 18,628,288 19,393,547 18,614,622 adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593	development costs		710		775		1,426		1,558		
Page	Amortization of intangible assets		325		337		651		674		
Share-based compensation expense 432 631 909 1,283 Loss on disposal of fixed assets — — — 1 34 Associate severances and other costs relating to transactions or corporate restructuring 110 67 110 206 Non-cash valuation adjustments to assets and liabilities 14 49 22 (1,173) Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 Other non-recurring income — — — — (750) Adjusted EBITDA Margin ⁽¹⁾ 21% 1,871 \$ 2,158 \$ 587 Adjusted EBITDA per diluted share 2 (0.06) \$ (0.05) \$ (0.16) \$ (0.16) Loss per share - diluted \$ (0.06) \$ (0.05) \$ (0.16) \$ (0.16) Adjusted EBITDA per adjusted diluted \$ (0.07) \$ (0.08) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) \$ (0.06) <	Amortization of other costs	_	36		7		80		48		
Loss on disposal of fixed assets Associate severances and other costs relating to transactions or corporate restructuring Non-cash valuation adjustments to assets and liabilities Transaction related professional fees, advisory fees and other internal direct costs Other non-recurring income Adjusted EBITDA Adjusted EBITDA Margin(1) Adjusted EBITDA per diluted share Loss per share - diluted Share (2) Diluted weighted average shares Includable incremental shares adjusted EBITDA (3) Diluted EBITDA (3) 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 110 206 206 206 206 206 206 206 206 206 20	EBITDA		769		1,117		861		967		
Associate severances and other costs relating to transactions or corporate restructuring 110 67 110 206 Non-cash valuation adjustments to assets and liabilities 14 49 9 22 (1,173) Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 Other non-recurring income ————————————————————————————————————	Share-based compensation expense	_	432		631		909		1,283		
relating to transactions or corporate restructuring 110 67 110 206 Non-cash valuation adjustments to assets and liabilities 14 49 22 (1,173) Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 Other non-recurring income 216 1,561 1,871 2,158 5 57	Loss on disposal of fixed assets		_		_		1		34		
Testructuring	Associate severances and other costs										
Non-cash valuation adjustments to assets and liabilities 14 49 22 (1,173) Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 Other non-recurring income ————————————————————————————————————	relating to transactions or corporate										
Adjusted EBITDA per diluted share Loss per share - diluted eBITDA per adjusted diluted share Loss per share - 20 Share 22 Share 23 S	restructuring		110		67		110		206		
Transaction related professional fees, advisory fees and other internal direct costs 236 7 255 20 Other non-recurring income ————————————————————————————————————	•										
advisory fees and other internal direct costs Other non-recurring income Adjusted EBITDA Adjusted EBITDA Margin ⁽¹⁾ Adjusted EBITDA per diluted share Loss per share - diluted Adjusted EBITDA per adjusted diluted share Loss per share - 3			14		49		22		(1,173)		
costs 236 7 255 20 Other non-recurring income — — — — (750) Adjusted EBITDA \$ 1,561 \$ 1,871 \$ 2,158 \$ 587 Adjusted EBITDA Margin ⁽¹⁾ 21% 22% 15% 4% Adjusted EBITDA per diluted share Loss per share - diluted \$ (0.06) \$ (0.05) \$ (0.16) \$ (0.16) Adjusted EBITDA per adjusted diluted share (2) \$ 0.07 \$ 0.09 \$ 0.10 \$ 0.03 Diluted weighted average shares Includable incremental shares — adjusted EBITDA (3) 19,791,805 18,628,288 19,393,547 18,614,622 adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593	•										
Other non-recurring income — — — — (750) Adjusted EBITDA \$ 1,561 \$ 1,871 \$ 2,158 \$ 587 Adjusted EBITDA Margin ⁽¹⁾ 21% 22% 15% 4% Adjusted EBITDA per diluted share \$ (0.06) \$ (0.05) \$ (0.16) \$ (0.16) Loss per share - diluted \$ (0.06) \$ (0.05) \$ (0.16) \$ (0.16) Adjusted EBITDA per adjusted diluted share \$ (0.07) \$ (0.09) \$ (0.10) \$ (0.03) Diluted weighted average shares Includable incremental shares — adjusted EBITDA (3) 19,791,805 18,628,288 19,393,547 18,614,622 adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593	•		220		7		255		20		
Adjusted EBITDA Margin ⁽¹⁾ \$ 1,561 \$ 1,871 \$ 2,158 \$ 587 Adjusted EBITDA Margin ⁽¹⁾ 21% 22% 15% 4% Adjusted EBITDA per diluted share Loss per share - diluted \$ (0.06) \$ (0.05) \$ (0.16) \$ (0.16) Adjusted EBITDA per adjusted diluted share share (2) \$ 0.07 \$ 0.09 \$ 0.10 \$ 0.03 Diluted weighted average shares Includable incremental shares — adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593			230		<i>I</i>		255				
Adjusted EBITDA Margin ⁽¹⁾ Adjusted EBITDA per diluted share Loss per share - diluted Adjusted EBITDA per adjusted diluted share (2) Diluted weighted average shares Includable incremental shares — adjusted EBITDA (3) Adjusted EBITDA (1) 121% 22% (0.05) (0.05) (0.16)	_		4 504	_	4.074	_	0.450	_			
Adjusted EBITDA per diluted share Loss per share - diluted Adjusted EBITDA per adjusted diluted share (2) Diluted weighted average shares Includable incremental shares — adjusted EBITDA (3) Solution (0.06) Solution (0.05) Solution (0.06) Solution (0.05) Solution (0.06) Solution (0.06	4.3	\$ <u>-</u>		\$		\$		\$			
Loss per share - diluted \$ (0.06) \$ (0.05) \$ (0.16) \$ (0.16) \$ (0.16) \$ Adjusted EBITDA per adjusted diluted share (2) \$ 0.07 \$ 0.09 \$ 0.10 \$ 0.03 \$ 0.03 \$ 0.10 \$ 0.03 \$ 0.03 \$ 0.10 \$ 0.03 \$ 0.03 \$ 0.00 \$ 0.10 \$ 0.03 \$ 0.00 \$,	-	21%		22%		15%_		4%		
Adjusted EBITDA per adjusted diluted share (2) \$ 0.07 \$ 0.09 \$ 0.10 \$ 0.03 Diluted weighted average shares 19,791,805 18,628,288 19,393,547 18,614,622 Includable incremental shares — adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593	Adjusted EBITDA per diluted share										
share (2) \$ 0.07 \$ 0.09 \$ 0.10 \$ 0.03 Diluted weighted average shares Includable incremental shares — adjusted EBITDA (3) 19,791,805 18,628,288 19,393,547 18,614,622 2,237,608 3,313,870 2,623,593	•	\$ _	(0.06)	\$	(0.05)	\$	(0.16)	\$	(0.16)		
Diluted weighted average shares 19,791,805 18,628,288 19,393,547 18,614,622 Includable incremental shares — adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593											
Includable incremental shares — 3,376,285 2,237,608 3,313,870 2,623,593 adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593	share ⁽²⁾	\$	0.07	\$	0.09	\$	0.10	\$	0.03		
Includable incremental shares — 3,376,285 2,237,608 3,313,870 2,623,593 adjusted EBITDA (3) 3,376,285 2,237,608 3,313,870 2,623,593											
adjusted EBITDA ⁽³⁾ 3,376,285 2,237,608 3,313,870 2,623,593	Diluted weighted average shares		19,791,805		18,628,288		19,393,547		18,614,622		
· ————————————————————————————————————	Includable incremental shares —										
Adjusted diluted shares 23,168,090 20,865,896 22,707,417 21,238,215	adjusted EBITDA ⁽³⁾	_	3,376,285		2,237,608		3,313,870		2,623,593		
	Adjusted diluted shares	_	23,168,090		20,865,896		22,707,417		21,238,215		

⁽¹⁾ Adjusted EBITDA as a percentage of GAAP revenues

⁽²⁾ Adjusted EBITDA per adjusted diluted share for the Company's common stock is computed using the more dilutive of the two-class method or the if-

converted method.

(3) The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed.

Logo - http://photos.prnewswire.com/prnh/20151208/294363LOGO

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/streamline-health-reports-second-quarter-2016-revenues-of-74-million-adjusted-ebitda-of-16-million-net-loss-of-07-million-300324161.html

SOURCE Streamline Health, Inc.

News Provided by Acquire Media